{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:35:48Z","timestamp":1792460148325,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:00:00Z","timestamp":1739059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","award":["SGZ-2022-13798"],"award-info":[{"award-number":["SGZ-2022-13798"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.gim.2025.101373","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T15:08:07Z","timestamp":1738940887000},"page":"101373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of transitioning from alglucosidase alfa to avalglucosidase alfa in infantile-onset Pompe disease: A single-center cohort analysis"],"prefix":"10.1016","volume":"27","author":[{"given":"Yin-Hsuan","family":"Chien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-An","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rai-Hseng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hua","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Ya","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni-Chung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-5728","authenticated-orcid":false,"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.gim.2025.101373_bib1","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/biom10091339","article-title":"Pompe disease: new developments in an old lysosomal storage disorder","volume":"10","author":"Meena","year":"2020","journal-title":"Biomolecules"},{"issue":"13","key":"10.1016\/j.gim.2025.101373_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.21037\/atm.2019.04.15","article-title":"Challenges in treating Pompe disease: an industry perspective","volume":"7","author":"Do","year":"2019","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.gim.2025.101373_bib3","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.bbrc.2017.12.101","article-title":"Four unreported types of glycans containing mannose-6-phosphate are heterogeneously attached at three sites (including newly found Asn 233) to recombinant human acid alpha-glucosidase that is the only approved treatment for Pompe disease","volume":"495","author":"Park","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"48","key":"10.1016\/j.gim.2025.101373_bib4","doi-asserted-by":"crossref","first-page":"50336","DOI":"10.1074\/jbc.M409676200","article-title":"Conjugation of mannose 6-phosphate-containing oligosaccharides to acid \u03b1-glucosidase improves the clearance of glycogen in Pompe mice","volume":"279","author":"Zhu","year":"2004","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.gim.2025.101373_bib5","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.gim.2025.101373_bib6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1042\/BJ20050364","article-title":"Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice","volume":"389","author":"Zhu","year":"2005","journal-title":"Biochem J"},{"issue":"6","key":"10.1016\/j.gim.2025.101373_bib7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","article-title":"Efficacy and safety of avalglucosidase Alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial","volume":"80","author":"Kishnani","year":"2023","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.gim.2025.101373_bib8","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.gim.2025.101373_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.gim.2025.101373_bib10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40265-023-01886-5","article-title":"Cipaglucosidase Alfa: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.gim.2025.101373_bib11","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00415-023-12096-0","article-title":"Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I\/II study (ATB200-02)","volume":"271","author":"Byrne","year":"2024","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.gim.2025.101373_bib12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.gim.2025.101373_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13023-016-0442-y","article-title":"Childhood Pompe disease: clinical spectrum and genotype in 31 patients","volume":"11","author":"van Capelle","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"15","key":"10.1016\/j.gim.2025.101373_bib14","doi-asserted-by":"crossref","first-page":"15856","DOI":"10.18632\/aging.103794","article-title":"Pompe disease: pathogenesis, molecular genetics and diagnosis","volume":"12","author":"Taverna","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.gim.2025.101373_bib15","article-title":"Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: evidence from real-world experiences","volume":"23","author":"Chien","year":"2020","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"10.1016\/j.gim.2025.101373_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13023-023-02981-2","article-title":"Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry","volume":"18","author":"Kishnani","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.gim.2025.101373_bib17","article-title":"Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"issue":"14","key":"10.1016\/j.gim.2025.101373_bib18","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1016\/S0021-9258(18)83136-2","article-title":"Ligand interactions of the cation-independent mannose 6-phosphate receptor. The stoichiometry of mannose 6-phosphate binding","volume":"264","author":"Tong","year":"1989","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.gim.2025.101373_bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0014-4827(84)90779-1","article-title":"Uptake and stability of human and bovine acid alpha-glucosidase in cultured fibroblasts and skeletal muscle cells from glycogenosis type II patients","volume":"155","author":"Reuser","year":"1984","journal-title":"Exp Cell Res"},{"issue":"4","key":"10.1016\/j.gim.2025.101373_bib20","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.gim.2025.101373_bib21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ymgme.2013.12.296","article-title":"Comparative study on mannose 6-phosphate residue contents of recombinant lysosomal enzymes","volume":"111","author":"Togawa","year":"2014","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.gim.2025.101373_bib22","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","article-title":"Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease","volume":"94","author":"McVie-Wylie","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"1-2","key":"10.1016\/j.gim.2025.101373_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108559","article-title":"Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease","volume":"143","author":"Kishnani","year":"2024","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2025.101373_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ajmg.c.31317","article-title":"Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten","volume":"160C","author":"Raben","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.gim.2025.101373_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100769","article-title":"Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase","volume":"296","author":"Selvan","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.gim.2025.101373_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.omtm.2017.03.006","article-title":"Engineering of GlcNAc-1-Phosphotransferase for production of highly phosphorylated lysosomal enzymes for enzyme replacement therapy","volume":"5","author":"Liu","year":"2017","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360025000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360025000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:53:20Z","timestamp":1762365200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360025000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1098360025000206"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2025.101373","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of transitioning from alglucosidase alfa to avalglucosidase alfa in infantile-onset Pompe disease: A single-center cohort analysis","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2025.101373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.","name":"copyright","label":"Copyright"}],"article-number":"101373"}}